Debiao Xiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Debiao Xiang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Lili Zhou
Hunan University of Chinese Medicine, 300 Xueshi Road, Yuelu District, Changsha, Hunan Province, 410208, China
2 shared publications- Lili Zhou
School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People’s Republic of China
2 shared publications - Xin Li
Department of Pharmacy, The Third Hospital of Changsha / The Affiliated Changsha Hospital of Hunan University, Hunan University
2 shared publications - Yating Shang
School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People’s Republic of China
2 shared publications Fang Yuan
Department of Pharmacy, The Third Hospital of Changsha, 176 Western Laodong Road, Tianxin District, Changsha, Hunan Province, 410015, China
1 shared publication- Fang Yuan
Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China
1 shared publication
Latest Publications
- Open Access
- 17 June 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (13) , 7537-7570
TAM-targeted nanomedicine in cancer: biological basis, therapeutic strategies, and translational perspectives
Tumor-associated macrophages (TAMs) are the most common immune cell type found in the tumor microenvironment. They are also key participants in the regulation of angiogenesis, metastasis, immune evasion, and therapeutic resistance. Recent single-cell transcriptomics and spatial profiling have shown that TAMs are extremely heterogeneous and functionally plastic beyond the traditional M1/M2 paradigm, and that more refined therapeutic strategies are required. Nanomedicine can integrate macrophage biology, the tumor microenvironment, and the engineering of the delivery system to design TAM-oriented interventions. With optimization of delivery systems (e.g. particle size, surface chemistry, ligands, therapeutic payloads, and the type of stimuli), multiple functionalities can be engineered to improve macrophage (in the tumor microenvironment) recruitment, depletion, reprogramming, and enhancement of TAM phagocytosis, antigen presentation, and immune regulation. Nanoparticles with biomimetic systems, macrophage membrane coating, as well as macrophage-derived extracellular vesicles and engineered exosome platforms, can also provide a wide array of options for TAM-oriented therapy. In this review, we provide an overview of the origin, heterogeneity, and functions of TAMs in cancer, and categorize TAM-targeted nanotherapeutics based on the principal approaches of recruitment blockade, tumor-promoting macrophage depletion, reprogramming, functional enhancement of phagocytosis and immune activation, and biomimetic drug delivery. We also present a comparison of representative nanoplatforms, highlight the latest clinical developments, and investigate key barriers to moving research from the lab to the clinic using nanomedicine, including delivery system design focused on targeting TAMs, safe and effective delivery to tumors, off-target effects on macrophages, ease of manufacture, and control of product quality. By combining TAM biology with the design of specialized nanocarriers and clinical research, this review outlines the main directions of research and provides a practical approach to the development of specialized TAM-targeted cancer nanomedicines.
- 17 June 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (13) , 7537-7570
Open AccessTAM-targeted nanomedicine in cancer: biological basis, therapeutic strategies, and translational perspectives
Tumor-associated macrophages (TAMs) are the most common immune cell type found in the tumor microenvironment. They are also key participants in the regulation of angiogenesis, metastasis, immune evasion, and therapeutic resistance. Recent single-cell transcriptomics and spatial profiling have shown that TAMs are extremely heterogeneous and functionally plastic beyond the traditional M1/M2 paradigm, and that more refined therapeutic strategies are required. Nanomedicine can integrate macrophage biology, the tumor microenvironment, and the engineering of the delivery system to design TAM-oriented interventions. With optimization of delivery systems (e.g. particle size, surface chemistry, ligands, therapeutic payloads, and the type of stimuli), multiple functionalities can be engineered to improve macrophage (in the tumor microenvironment) recruitment, depletion, reprogramming, and enhancement of TAM phagocytosis, antigen presentation, and immune regulation. Nanoparticles with biomimetic systems, macrophage membrane coating, as well as macrophage-derived extracellular vesicles and engineered exosome platforms, can also provide a wide array of options for TAM-oriented therapy. In this review, we provide an overview of the origin, heterogeneity, and functions of TAMs in cancer, and categorize TAM-targeted nanotherapeutics based on the principal approaches of recruitment blockade, tumor-promoting macrophage depletion, reprogramming, functional enhancement of phagocytosis and immune activation, and biomimetic drug delivery. We also present a comparison of representative nanoplatforms, highlight the latest clinical developments, and investigate key barriers to moving research from the lab to the clinic using nanomedicine, including delivery system design focused on targeting TAMs, safe and effective delivery to tumors, off-target effects on macrophages, ease of manufacture, and control of product quality. By combining TAM biology with the design of specialized nanocarriers and clinical research, this review outlines the main directions of research and provides a practical approach to the development of specialized TAM-targeted cancer nanomedicines.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-40
Key Tumor Responsive ZIF-8 Nanocarriers for Effective Anti-Cancer Therapeutics
The intricate pathological features of the tumor microenvironment (TME) collectively contribute to therapeutic resistance, thereby substantially constraining the antitumor efficacy of conventional treatments. Zeolitic imidazolate framework-8 (ZIF-8), a pH-responsive metal-organic framework material, serves not only as an efficient drug delivery system but also actively participates in TME remodeling through the release of Zn2+ upon its degradation. This dual function as both a “carrier” and an “effector” offers a synergistic mechanism to mitigate therapeutic resistance. The article reviews recent research on ZIF-8, focusing on its role in targeted drug delivery and its transformation from a passive carrier to an active modulator of cellular environments. It examines how ZIF-8’s synthetic pathways and surface modifications aid in delivering various drugs and analyzes the molecular mechanisms by which released Zn2+ triggers stress responses and immune reactions. The article also discusses ZIF-8’s integration into theranostic platforms, its use in combination therapies, and the clinical translation challenges, including biosafety, reproducibility, and scalable production. This review aims to systematically synthesize existing knowledge across the aforementioned fields to establish a theoretical foundation for the design of next-generation ZIF-8 nanotheranostic systems and facilitate their progression toward clinical translation. The infographic illustrates the TME-responsive ZIF-8 nanoplatform for cancer therapy. It begins with the synthesis process, showing Zn superscript 2 plus and 2-Methylimidazole forming ZIF-8, which is then functionalized with drugs for EPR effect and ligand targeting. The acidic TME-responsive degradation leads to drug and Zn superscript 2 plus release. Combination therapies include chemotherapy, radiotherapy and immunotherapy. The dual ’Carrier-Effecter’ mechanism involves pH-responsive drug and Zn superscript 2 plus release targeting cancerous tumors, leading to DAMPs release, ICD, ROS production and activation of caspase and GSDMD. This process stimulates maturation and activation of DCs and mDCs, enhancing CD8 superscript plus T cells and CD4 superscript plus T cells. Theranostics involve imaging (MRI, PET) and image-guided therapy. The outlook emphasizes rational design, scalable synthesis, multifunctionality, clinical translation and personalized precision medicine.TME-responsive ZIF-8 nanoplatform: cancer therapy with theranostics and dual strategies.
- 1 May 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-40
Open AccessKey Tumor Responsive ZIF-8 Nanocarriers for Effective Anti-Cancer Therapeutics
The intricate pathological features of the tumor microenvironment (TME) collectively contribute to therapeutic resistance, thereby substantially constraining the antitumor efficacy of conventional treatments. Zeolitic imidazolate framework-8 (ZIF-8), a pH-responsive metal-organic framework material, serves not only as an efficient drug delivery system but also actively participates in TME remodeling through the release of Zn2+ upon its degradation. This dual function as both a “carrier” and an “effector” offers a synergistic mechanism to mitigate therapeutic resistance. The article reviews recent research on ZIF-8, focusing on its role in targeted drug delivery and its transformation from a passive carrier to an active modulator of cellular environments. It examines how ZIF-8’s synthetic pathways and surface modifications aid in delivering various drugs and analyzes the molecular mechanisms by which released Zn2+ triggers stress responses and immune reactions. The article also discusses ZIF-8’s integration into theranostic platforms, its use in combination therapies, and the clinical translation challenges, including biosafety, reproducibility, and scalable production. This review aims to systematically synthesize existing knowledge across the aforementioned fields to establish a theoretical foundation for the design of next-generation ZIF-8 nanotheranostic systems and facilitate their progression toward clinical translation. The infographic illustrates the TME-responsive ZIF-8 nanoplatform for cancer therapy. It begins with the synthesis process, showing Zn superscript 2 plus and 2-Methylimidazole forming ZIF-8, which is then functionalized with drugs for EPR effect and ligand targeting. The acidic TME-responsive degradation leads to drug and Zn superscript 2 plus release. Combination therapies include chemotherapy, radiotherapy and immunotherapy. The dual ’Carrier-Effecter’ mechanism involves pH-responsive drug and Zn superscript 2 plus release targeting cancerous tumors, leading to DAMPs release, ICD, ROS production and activation of caspase and GSDMD. This process stimulates maturation and activation of DCs and mDCs, enhancing CD8 superscript plus T cells and CD4 superscript plus T cells. Theranostics involve imaging (MRI, PET) and image-guided therapy. The outlook emphasizes rational design, scalable synthesis, multifunctionality, clinical translation and personalized precision medicine.TME-responsive ZIF-8 nanoplatform: cancer therapy with theranostics and dual strategies.
- Top Cited PapersOpen Access
- 1 May 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 6891-6927
Nanoagent-Mediated Photothermal Therapy: From Delivery System Design to Synergistic Theranostic Applications
In contemporary medicine, cancer poses a perilous threat to human life, health, and quality of life, remaining a central focus of medical research and clinical practice. Although traditional cancer treatments, such as surgery, chemotherapy, and radiotherapy, have demonstrated some degree of success, they continue to encounter substantial challenges, including incomplete tumor eradication and the occurrence of severe adverse effects. Therefore, there is an urgent need to develop novel cancer treatment strategies characterized by high efficacy, low toxicity, and precise targeting. Photothermal therapy (PTT), as a newly emerging approach, holds considerable promise due to its unique mechanism of action. Upon laser irradiation, PTT utilizes a photothermal agent (PTA) to transform light energy into thermal energy, thereby inducing localized hyperthermia within tumor tissues. This process enables precise ablation of tumor cells while minimizing damage to surrounding healthy tissues. Recent advancements in photothermal agent research have yielded a diverse array of PTAs, and the synergistic integration of PTT with diagnostic and therapeutic techniques has further expanded its therapeutic efficacy and clinical applicability. This paper will provide an overview of the mechanisms underlying PTT, recent progress in photothermal agent development, synergistic theranostic strategies, and combined therapeutic approaches. The aim is to establish a foundation for optimizing PTAs design, elucidating PTT mechanisms, and advancing research on synergistic therapeutic protocols. Ultimately, these endeavors have the potential to result in more effective and safer disease treatments, thereby advancing the translation of photothermal therapy from foundational research to broad clinical application.
- 1 May 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 6891-6927
Top Cited PapersOpen AccessNanoagent-Mediated Photothermal Therapy: From Delivery System Design to Synergistic Theranostic Applications
In contemporary medicine, cancer poses a perilous threat to human life, health, and quality of life, remaining a central focus of medical research and clinical practice. Although traditional cancer treatments, such as surgery, chemotherapy, and radiotherapy, have demonstrated some degree of success, they continue to encounter substantial challenges, including incomplete tumor eradication and the occurrence of severe adverse effects. Therefore, there is an urgent need to develop novel cancer treatment strategies characterized by high efficacy, low toxicity, and precise targeting. Photothermal therapy (PTT), as a newly emerging approach, holds considerable promise due to its unique mechanism of action. Upon laser irradiation, PTT utilizes a photothermal agent (PTA) to transform light energy into thermal energy, thereby inducing localized hyperthermia within tumor tissues. This process enables precise ablation of tumor cells while minimizing damage to surrounding healthy tissues. Recent advancements in photothermal agent research have yielded a diverse array of PTAs, and the synergistic integration of PTT with diagnostic and therapeutic techniques has further expanded its therapeutic efficacy and clinical applicability. This paper will provide an overview of the mechanisms underlying PTT, recent progress in photothermal agent development, synergistic theranostic strategies, and combined therapeutic approaches. The aim is to establish a foundation for optimizing PTAs design, elucidating PTT mechanisms, and advancing research on synergistic therapeutic protocols. Ultimately, these endeavors have the potential to result in more effective and safer disease treatments, thereby advancing the translation of photothermal therapy from foundational research to broad clinical application.
- Open Access
- 1 December 2024
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 19, 12975-12998
A Novel Triptolide Nano-Liposome with Mitochondrial Targeting for Treatment of Hepatocellular Carcinoma
Background: Modern pharmacological studies have demonstrated that although triptolide (TP) is effective against hepatocellular carcinoma, it has poor water solubility and more toxic side effects. In this study, we used triptolide (TP), a bioactive constituent in Tripterygium wilfordii Hook F, as a model drug to develop a novel nano-liposome drug delivery system for the treatment of liver tumours. Methods: We constructed a functionally-modified triptolide liposome (FA+TPP-TP-Lips) using the film-dispersion method and investigated its physicochemical properties, mitochondrial targeting of hepatic tumour cells, in vitro and in vivo anti-hepatic tumour activity and its mechanism. Results: The prepared FA+TPP-TP-Lips had a particle size of 99.28 ± 5.7 nm, a PDI of 0.20 ± 0.02, a zeta potential of 1.2 ± 0.08 mV, and an encapsulation rate of 74.37% ± 1.07%.FA+TPP-TP-Lips facilitates the cellular uptake of drug delivery systems and improves their targeted delivery to mitochondria. The results of cell efficacy showed that FA+TPP-TP-Lips significantly inhibited the growth of liver cancer cells, decreased mitochondrial membrane potential, and increased intracellular ROS, thus enhancing the highest apoptosis rate of liver cancer cells. The targeted liposomes (FA-TP-Lips, TPP-TP-Lips, and FA+TPP-TP-Lips) had some degree of inhibitory migration effect on Huh-7 cells relative to the unmodified TP-Lips. Studies on tumor-bearing mice demonstrated that FA+ TPP-TP-Lips effectively accumulated in tumor tissues and significantly inhibited the growth of subcutaneous tumors, achieving a tumor inhibition rate of 79.37%. FA+ TPP-TP-Lips demonstrated an enhanced anti-liver tumor effect and significantly mitigated the hepatotoxicity and systemic toxicity associated with TP. Conclusion: In summary, the results of this study can provide a feasible solution for improving the mitochondrial targeting of nano-liposomes, and lay a foundation for further developing a novel nano targeting preparation of triptolide for the treatment of hepatocellular carcinoma.
- 1 December 2024
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 19, 12975-12998
Open AccessA Novel Triptolide Nano-Liposome with Mitochondrial Targeting for Treatment of Hepatocellular Carcinoma
Background: Modern pharmacological studies have demonstrated that although triptolide (TP) is effective against hepatocellular carcinoma, it has poor water solubility and more toxic side effects. In this study, we used triptolide (TP), a bioactive constituent in Tripterygium wilfordii Hook F, as a model drug to develop a novel nano-liposome drug delivery system for the treatment of liver tumours. Methods: We constructed a functionally-modified triptolide liposome (FA+TPP-TP-Lips) using the film-dispersion method and investigated its physicochemical properties, mitochondrial targeting of hepatic tumour cells, in vitro and in vivo anti-hepatic tumour activity and its mechanism. Results: The prepared FA+TPP-TP-Lips had a particle size of 99.28 ± 5.7 nm, a PDI of 0.20 ± 0.02, a zeta potential of 1.2 ± 0.08 mV, and an encapsulation rate of 74.37% ± 1.07%.FA+TPP-TP-Lips facilitates the cellular uptake of drug delivery systems and improves their targeted delivery to mitochondria. The results of cell efficacy showed that FA+TPP-TP-Lips significantly inhibited the growth of liver cancer cells, decreased mitochondrial membrane potential, and increased intracellular ROS, thus enhancing the highest apoptosis rate of liver cancer cells. The targeted liposomes (FA-TP-Lips, TPP-TP-Lips, and FA+TPP-TP-Lips) had some degree of inhibitory migration effect on Huh-7 cells relative to the unmodified TP-Lips. Studies on tumor-bearing mice demonstrated that FA+ TPP-TP-Lips effectively accumulated in tumor tissues and significantly inhibited the growth of subcutaneous tumors, achieving a tumor inhibition rate of 79.37%. FA+ TPP-TP-Lips demonstrated an enhanced anti-liver tumor effect and significantly mitigated the hepatotoxicity and systemic toxicity associated with TP. Conclusion: In summary, the results of this study can provide a feasible solution for improving the mitochondrial targeting of nano-liposomes, and lay a foundation for further developing a novel nano targeting preparation of triptolide for the treatment of hepatocellular carcinoma.
- Open Access
- 6 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (36) , e39567
Spotlight on endoplasmic reticulum stress in acute kidney injury: A bibliometric analysis and visualization from 1997 to 2024
Background: Endoplasmic reticulum (ER) stress, a protective stress response of body and play important role in maintain ER stability. Acute kidney injury (AKI) is a severe syndrome, and the molecular mechanisms of AKI has not been fully elucidated. With an increasing understanding of ER stress, ER stress has been investigated and considered a potential and novel therapeutic target in AKI. This study aims to employ a bibliometric approach to analyze research trends and focal points in ER stress associated with AKI over 3 decades. Methods: Data were retrieved from the Web of Science Core Collection on April 15, 2024. CiteSpace and VOSviewer bibliometric software were mainly used to measure bibliometrics and analyze knowledge graphs to predict the latest research trends in the field. Results: There were 452 “ER stress in AKI” articles in the Web of Science Core Collection. According to the report, China and the United States were the leading research drivers in this field. Central South University was the most active academic institution, contributing the most documents. In this field, Dong Zheng was the most prolific author. The American Journal of Physiology-Renal Physiology was the journal with the most records among all journals. The keywords “NLRP3 inflammasome,” “redox signaling,” and novel forms of cell death such as “ferroptosis” may represent current research trends and directions. Conclusion: The bibliometric analysis comprehensively examines the trends and hotspots on “ER stress and AKI.” Studies on AKI related to stress in the ER are still in their infancy. Research should focus on understanding the relationship between ER stress and inflammasome, redox signal pathways and new forms of cell death such as ferroptosis.
- 6 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (36) , e39567
Open AccessSpotlight on endoplasmic reticulum stress in acute kidney injury: A bibliometric analysis and visualization from 1997 to 2024
Background: Endoplasmic reticulum (ER) stress, a protective stress response of body and play important role in maintain ER stability. Acute kidney injury (AKI) is a severe syndrome, and the molecular mechanisms of AKI has not been fully elucidated. With an increasing understanding of ER stress, ER stress has been investigated and considered a potential and novel therapeutic target in AKI. This study aims to employ a bibliometric approach to analyze research trends and focal points in ER stress associated with AKI over 3 decades. Methods: Data were retrieved from the Web of Science Core Collection on April 15, 2024. CiteSpace and VOSviewer bibliometric software were mainly used to measure bibliometrics and analyze knowledge graphs to predict the latest research trends in the field. Results: There were 452 “ER stress in AKI” articles in the Web of Science Core Collection. According to the report, China and the United States were the leading research drivers in this field. Central South University was the most active academic institution, contributing the most documents. In this field, Dong Zheng was the most prolific author. The American Journal of Physiology-Renal Physiology was the journal with the most records among all journals. The keywords “NLRP3 inflammasome,” “redox signaling,” and novel forms of cell death such as “ferroptosis” may represent current research trends and directions. Conclusion: The bibliometric analysis comprehensively examines the trends and hotspots on “ER stress and AKI.” Studies on AKI related to stress in the ER are still in their infancy. Research should focus on understanding the relationship between ER stress and inflammasome, redox signal pathways and new forms of cell death such as ferroptosis.